Kann endovasc (ENDV.Nap)auf lange Sicht ein neuer Biotech Knaller werden? - 500 Beiträge pro Seite

[spidermonster]

Vielleicht kennt jemand diese Aktie. Sie steht zur Zeit auf 50 Cents und wird an der Nasdaq gehandelt. Nachdem sie ein Hoch laut comdirekt von 15 Us Dollars hatte fiel sie auf 50 Cents, jedoch kann man seit längerer Zeit eine Bodenbildung erkennen. Begibt man sich in den amerikanischen Finanzbereich von yahoo und verfolgt die Nachrichten über endovasc so stellt man fest daß sich hier etwas zu bewegen scheint . Komischerweise unterscheiden sich aber die Allzeithochs zwischen yahoo-finance und comdirekt. Hat jemand eine Erklärung dazu?

[[KERN]Codex]

Hey Spidermonster

Finde ich gut, dass du auch Interesse an diesem Unternehmen zeigst!
Es laufen derzeit 2 Beiträge zu Endovasc!!
Einer von menatwork00 (hier der Link) : Thread: Endovasc - junger Biotech-Starter !!!
und einer von mir : Thread: Discovery Expo in den USA>>>>Endovasc Ltd., Inc.<<<
In diesen beiden Threads findest du alle Informationen, die du brauchst, um eine
Anlage Entscheidung zu treffen!

Gruß Codex

bin auch dick investiert

[spidermonster]

Nochmals hallo
Hier sind die letzten Neuigkeiten zu endovasc, hört sich eigentlich ziemlich positiv an

Wednesday November 1, 8:31 am Eastern Time
Press Release
Endovasc Applauds New Partnership With Dow Chemical`s Acquisition of Collaborative BioAlliance
MONTGOMERY, Texas--(BUSINESS WIRE)--Nov. 1, 2000--Endovasc Ltd. Inc. (OTCBB:ENDV - news) today reported that its relationship with Collaborative BioAlliance was significantly enhanced with the Oct. 20, 2000, announcement of The Dow Chemical Company`s acquisition of The Collaborative Group, Ltd. Biotechnology Services Division, specifically Collaborative BioAlliance Inc.(CBA) and Collaborative Smithfield Corp.

Dow`s vast experience in manufacturing, research and development and process optimization, will expand CBA`s existing expertise in contract process development and manufacturing services for a wide range of biopharmaceutical products. Dow now has an opportunity to be among the leaders in biopharmaceutical contract development and manufacturing services.

In September 1999, Endovasc announced that Collaborative completed the pilot phase in the production of Liprostin(TM), and then followed in February 2000 with the completion of the current good manufacturing practices (cGMP). On May 22, 2000, Endovasc`s Chairman and CEO, Dr. David Summers announced that Collaborative BioAlliance had done an outstanding job in bringing Liprostin(TM) into a product reality by completion of the final manufacturing requirement, the certified Chemistry, Manufacturing and Controls (CMC).

Endovasc will continue business as usual with Collaborative BioAlliance/Dow, having just completed and submitted its first liposomal drug product to the Federal Drug Administration. ``It is hard to imagine the strength Dow will bring,`` said Endovasc`s Chairman, Dr. David Summers. ``We look forward to their continued success and our continued strong working relationship.``

Susan Dexter, vice president of CBA/Dow said, ``We will continue to be an advocate for your (Endovasc`s) project with Dow, and are enthused that we will have the opportunity to grow a world-class Contract Development/Contract Manufacturing Organization at a faster rate than before.``

Endovasc Ltd. Inc. is a biotech/biopharmaceutical company pioneering liposomal and stent drug delivery technology. The company`s products and processes are covered by patents and trade secrets for competing in a multi-billion dollar market.

The foregoing statements are made under the ``Safe Harbor`` Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc Ltd. Inc., contact:


--------------------------------------------------------------------------------
Contact:

Endovasc Ltd. Inc., Houston
Barbara Richardson, 936/448-2222
Fax: [phone]
E-mail: [e-mail]
Web site: www.endovasc.com
or
The Dilenschneider Group Inc., New York
Dick Kosmicki, 212/922-0900
E-mail: [e-mail]
or
Matt Swetonic, 212/922-0900
E-mail: [e-mail]
Fax: [phone]

[[KERN]Codex]

Jo die News hier sind zwar schon "alt", aber es zeigt ja, dass du dich fuer ENDV interessierst
und dir auch eine Meinung bilden willsd!!

Gruß Codex